Neurokine Pharmaceuticals Inc. - FORM 10-Q/A - XML - IDEA: XBRL DOCUMENT - December 21, 2011



Attached files
FileFilename
XML - IDEA: XBRL DOCUMENT - Neurokine Pharmaceuticals Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Neurokine Pharmaceuticals Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Neurokine Pharmaceuticals Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Neurokine Pharmaceuticals Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Neurokine Pharmaceuticals Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Neurokine Pharmaceuticals Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Neurokine Pharmaceuticals Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Neurokine Pharmaceuticals Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Neurokine Pharmaceuticals Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Neurokine Pharmaceuticals Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Neurokine Pharmaceuticals Inc.R2.htm
EXCEL - IDEA: XBRL DOCUMENT - Neurokine Pharmaceuticals Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - Neurokine Pharmaceuticals Inc.R9.htm
10-Q/A - FORM 10-Q/A - Neurokine Pharmaceuticals Inc.neurokineform10qaxbrlq2july3.htm
v2.4.0.6
NEUROKINE PHARMACEUTICALS INC. - Statements of Operations (USD $)
3 Months Ended 6 Months Ended 110 Months Ended
Jul. 31, 2011
Jul. 31, 2010
Jul. 31, 2011
Jul. 31, 2010
Jul. 31, 2011
EXPENSES          
Amortization $ 114   $ 228   $ 266
Foreign exchange (gain) loss 1,274 (395) 1,545 (213) (7,792)
General and administrative 29,575 11,646 130,685 22,276 265,462
Management fees 17,026 [1] 8,076 [1] 32,860 [1] 14,476 [1] 111,836 [1]
Professional fees 12,029 23,194 32,886 33,032 128,983
Research and development 13,333   48,541   273,215
Royalties         500,000
TOTAL EXPENSES 73,351 42,521 246,745 69,571 1,287,554
Loss from operations (73,351) (42,521) (246,745) (69,571) (1,287,554)
Accretion of discount on convertible debt (45,705) [2]   (75,151) [2]   (85,849) [2]
Gain (loss) on change in fair value of derivative liability 262,696 [3]   2,584,613 [3]   (283,411) [3]
Interest expense (10,018)   (14,203)   (14,203)
Total Other Income (Expenses) 206,923   2,495,259   (383,463)
Net Income (Loss) 133,622 (42,521) 2,248,514 (69,571) (1,671,017)
Net income (loss) per share, basic     0.07    
Net income (loss) per share, diluted     $ 0.06    
Weighted average shares outstanding, basic 33,790,788 24,020,575 33,707,605 23,952,137  
Weighted average shares outstanding, diluted 38,513,886 24,020,575 38,456,224 23,952,137  
[1] See Note 9
[2] See Note 5
[3] See Note 6

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA



This web site and associated pages are not associated with, endorsed by, or sponsored by Neurokine Pharmaceuticals Inc. and has no official or unofficial affiliation with Neurokine Pharmaceuticals Inc.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.